Annual EBITDA
-$24.94 M
+$69.03 M+73.46%
December 31, 2023
Summary
- As of February 7, 2025, YMAB annual EBITDA is -$24.94 million, with the most recent change of +$69.03 million (+73.46%) on December 31, 2023.
- During the last 3 years, YMAB annual EBITDA has risen by +$94.60 million (+79.14%).
- YMAB annual EBITDA is now -46.35% below its all-time high of -$17.04 million, reached on December 31, 2016.
Performance
YMAB EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$8.45 M
+$1.19 M+12.34%
September 30, 2024
Summary
- As of February 7, 2025, YMAB quarterly EBITDA is -$8.45 million, with the most recent change of +$1.19 million (+12.34%) on September 30, 2024.
- Over the past year, YMAB quarterly EBITDA has dropped by -$5.41 million (-178.04%).
- YMAB quarterly EBITDA is now -124.93% below its all-time high of $33.88 million, reached on March 31, 2021.
Performance
YMAB Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$27.87 M
-$866.00 K-3.21%
September 30, 2024
Summary
- As of February 7, 2025, YMAB TTM EBITDA is -$27.87 million, with the most recent change of -$866.00 thousand (-3.21%) on September 30, 2024.
- Over the past year, YMAB TTM EBITDA has dropped by -$2.93 million (-11.76%).
- YMAB TTM EBITDA is now -625.40% below its all-time high of -$3.84 million, reached on September 30, 2017.
Performance
YMAB TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
YMAB EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +73.5% | -178.0% | -11.8% |
| 3 y3 years | +79.1% | -815.2% | +70.3% |
| 5 y5 years | +42.3% | -815.2% | +70.3% |
YMAB EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +73.5% | -815.2% | +78.8% | -22.1% | +78.8% |
| 5 y | 5-year | at high | +79.1% | -124.9% | +79.1% | -22.1% | +78.8% |
| alltime | all time | -46.4% | +79.1% | -124.9% | +79.1% | -625.4% | +78.8% |
Y-mAbs Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$8.45 M(-12.3%) | -$27.87 M(+3.2%) |
| Jun 2024 | - | -$9.64 M(+42.8%) | -$27.00 M(+10.8%) |
| Mar 2024 | - | -$6.75 M(+122.2%) | -$24.37 M(-2.3%) |
| Dec 2023 | -$24.94 M(-73.5%) | -$3.04 M(-59.9%) | -$24.94 M(+9.3%) |
| Sep 2023 | - | -$7.58 M(+8.3%) | -$22.82 M(-44.4%) |
| Jun 2023 | - | -$7.00 M(-4.4%) | -$41.03 M(-44.4%) |
| Mar 2023 | - | -$7.32 M(+693.0%) | -$73.79 M(-21.5%) |
| Dec 2022 | -$93.97 M(+78.5%) | -$923.00 K(-96.4%) | -$93.97 M(-26.9%) |
| Sep 2022 | - | -$25.79 M(-35.1%) | -$128.51 M(-2.1%) |
| Jun 2022 | - | -$39.76 M(+44.6%) | -$131.28 M(+15.1%) |
| Mar 2022 | - | -$27.50 M(-22.5%) | -$114.02 M(+116.6%) |
| Dec 2021 | -$52.64 M(-56.0%) | -$35.47 M(+24.2%) | -$52.64 M(+41.7%) |
| Sep 2021 | - | -$28.56 M(+27.0%) | -$37.15 M(-9.7%) |
| Jun 2021 | - | -$22.50 M(-166.4%) | -$41.14 M(-30.3%) |
| Mar 2021 | - | $33.88 M(-269.6%) | -$59.00 M(-50.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | -$119.54 M(+44.3%) | -$19.98 M(-38.6%) | -$119.54 M(-3.0%) |
| Sep 2020 | - | -$32.55 M(-19.3%) | -$123.24 M(+7.2%) |
| Jun 2020 | - | -$40.35 M(+51.4%) | -$115.00 M(+23.3%) |
| Mar 2020 | - | -$26.66 M(+12.6%) | -$93.27 M(+12.6%) |
| Dec 2019 | -$82.84 M(+91.8%) | -$23.68 M(-2.6%) | -$82.84 M(+13.1%) |
| Sep 2019 | - | -$24.31 M(+30.6%) | -$73.22 M(+21.4%) |
| Jun 2019 | - | -$18.61 M(+14.7%) | -$60.32 M(+16.1%) |
| Mar 2019 | - | -$16.23 M(+15.4%) | -$51.96 M(+20.3%) |
| Dec 2018 | -$43.20 M(+124.5%) | -$14.06 M(+23.3%) | -$43.20 M(+12.5%) |
| Sep 2018 | - | -$11.41 M(+11.3%) | -$38.41 M(+24.5%) |
| Jun 2018 | - | -$10.25 M(+37.1%) | -$30.85 M(+49.8%) |
| Mar 2018 | - | -$7.48 M(-19.4%) | -$20.60 M(+57.0%) |
| Dec 2017 | -$19.24 M(+12.9%) | -$9.28 M(+141.4%) | -$13.12 M(+241.4%) |
| Sep 2017 | - | -$3.84 M | -$3.84 M |
| Dec 2016 | -$17.04 M | - | - |
FAQ
- What is Y-mAbs Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics annual EBITDA year-on-year change?
- What is Y-mAbs Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics quarterly EBITDA year-on-year change?
- What is Y-mAbs Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics TTM EBITDA year-on-year change?
What is Y-mAbs Therapeutics annual EBITDA?
The current annual EBITDA of YMAB is -$24.94 M
What is the all time high annual EBITDA for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high annual EBITDA is -$17.04 M
What is Y-mAbs Therapeutics annual EBITDA year-on-year change?
Over the past year, YMAB annual EBITDA has changed by +$69.03 M (+73.46%)
What is Y-mAbs Therapeutics quarterly EBITDA?
The current quarterly EBITDA of YMAB is -$8.45 M
What is the all time high quarterly EBITDA for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high quarterly EBITDA is $33.88 M
What is Y-mAbs Therapeutics quarterly EBITDA year-on-year change?
Over the past year, YMAB quarterly EBITDA has changed by -$5.41 M (-178.04%)
What is Y-mAbs Therapeutics TTM EBITDA?
The current TTM EBITDA of YMAB is -$27.87 M
What is the all time high TTM EBITDA for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high TTM EBITDA is -$3.84 M
What is Y-mAbs Therapeutics TTM EBITDA year-on-year change?
Over the past year, YMAB TTM EBITDA has changed by -$2.93 M (-11.76%)